AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 31 min read$NTRA

Moshkevich Solomon sold $1.2M of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,000 shares of Natera, Inc. (NTRA) at an average of $414.22 ($411.62–$415.07, $1.24M total) across 3 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Oct 3, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale is modest in size and likely to have limited price effect, but traders may watch for any follow‑up activity.

02

Market read

Routine insider sale with limited immediate market impact; monitor for further insider activity or upcoming clinical trial news.

03

What to watch

Potential upcoming clinical data releases could outweigh the sell signal.

Relevance 5/10Novelty 4/10Timing: after-hours filing

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

President of Clinical Diagnostics sold 3,000 shares for $1.24M via a 10b5-1 plan.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $1.2M open‑market sale by a senior officer can be interpreted as a neutral to slightly bearish signal, but the amount is modest for a mid‑cap biotech.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be purely procedural under a 10b5‑1 plan and not reflect confidence.

Key entities

  • Company
    Natera, Inc.

    US‑listed genetic testing company (ticker NTRA).

  • Person
    Moshkevich Solomon

    President, Clinical Diagnostics at Natera.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

OCT 6
$NTRAMedAI 8/10

Why is Natera stock sliding today?

Natera (NTRA) stock fell 6.0% after hitting a 52-week high, despite positive news. Citi raised its price target to $480, and Natera announced new data and a trial. Insider selling and high valuation contributed to the decline. The broader market advanced, indicating the move was company-specific.

investing.com2 min
SEP 23
$NTRAHighAI 9/10

We flagged it early: This diagnostics stock is up +22% after a regulatory win

Natera (NTRA) shares rose 4.5% to a 52-week high of $387.44 after Japan's PMDA approved its Signatera test for bladder cancer. The stock is up 22% since early September. Natera reported record Signatera unit additions and 37.7% revenue growth. Marvell (MRVL) also gained, up 24.7% this month. Investing.com's AI strategies outperformed benchmarks, with Healthcare Heroes up 2.67% this month.

investing.com2 min
SEP 22
$NTRAMedAI 8/10

Why Is Natera (NTRA) Stock Soaring Today

Natera (NTRA) stock rose 5.2% after Japan approved its Signatera test for bladder cancer. The company plans a 2027 commercial launch in Japan. Shares later cooled to $387.44, up 4.5%. Natera's revenue grew 38.8% YoY to $696.6M, but its loss widened to $0.60 per share, missing estimates.

financialcontent.com2 min